


PRODUCT INFORMATION



LAS191859

Item No. 20238

CAS Registry No.: 1420071-13-1
Formal Name: 1-[2-[(cyclopropylcarbonyl)ethylamino]methyl]-4-(trifluoromethyl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridine-3-acetic acid
MF: C₂₄H₂₄F₃N₃O₃
FW: 459.5
Purity: ≥98%
UV/Vis.: λ_{max}: 272 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

LAS191859 is supplied as a crystalline solid. A stock solution may be made by dissolving the LAS191859 in the solvent of choice. LAS191859 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of LAS191859 in ethanol is approximately 2.5 mg/ml and approximately 20 mg/ml in DMSO and DMF.

LAS191859 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, LAS191859 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. LAS191859 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

LAS191859 is a potent antagonist of CRTH2/DP₂ with IC₅₀ values of 9.58, 14, 15.5, and 7.6 nM for recombinant human, rat, mouse, and guinea pig CRTH2/DP₂ receptors, respectively.¹ It is selective for CRTH2/DP₂ over a panel of 65 enzymes, ion channels, and transporters with <25% inhibition for all targets when tested at a concentration of 10 μM. LAS191859 reduces shape change of eosinophils (IC₅₀s = 2 and 8.2 nM in isolated eosinophils and whole blood, respectively) and eosinophil chemotaxis (IC₅₀ = 1.3 nM) induced by prostaglandin D₂ (PGD₂; Item No. 12010) binding to CRTH2/DP₂. Oral administration of LAS191859 reduces PGD₂-induced systemic eosinophilia in guinea pigs (ID₅₀ = 131 μg/kg).

Reference

1. Calbet, M., Andrés, M., Armengol, M., *et al.* Pharmacological characterization of CRTH2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy. *Pharmacol. Res.* **111**, 208-216 (2016).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/27/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM